End-of-day quote
Taipei Exchange
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
207
TWD
|
-2.13%
|
|
+3.50%
|
+5.88%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,656
|
9,043
|
9,856
|
13,013
|
15,025
|
14,338
|
Enterprise Value (EV)
1 |
4,858
|
8,485
|
9,484
|
11,703
|
13,773
|
13,009
|
P/E ratio
|
-77.1
x
|
-96
x
|
-92.1
x
|
35.4
x
|
75.3
x
|
27.1
x
|
Yield
|
-
|
-
|
-
|
2.38%
|
0.9%
|
1.79%
|
Capitalization / Revenue
|
-
|
835,885,008
x
|
139,609,331
x
|
29,652,400
x
|
23,943,663
x
|
18,905,448
x
|
EV / Revenue
|
-
|
784,288,835
x
|
134,343,230
x
|
26,668,891
x
|
21,948,957
x
|
17,152,867
x
|
EV / EBITDA
|
-55.7
x
|
-68.8
x
|
-69.9
x
|
82.7
x
|
44.8
x
|
36.4
x
|
EV / FCF
|
-70.7
x
|
-100
x
|
-64
x
|
117
x
|
62.7
x
|
42.7
x
|
FCF Yield
|
-1.41%
|
-1%
|
-1.56%
|
0.86%
|
1.59%
|
2.34%
|
Price to Book
|
6.07
x
|
10.7
x
|
12.7
x
|
6.86
x
|
8.38
x
|
7.78
x
|
Nbr of stocks (in thousands)
|
67,738
|
67,738
|
67,738
|
74,776
|
74,931
|
73,339
|
Reference price
2 |
83.50
|
133.5
|
145.5
|
174.0
|
200.5
|
195.5
|
Announcement Date
|
4/30/19
|
4/27/20
|
3/26/21
|
3/28/22
|
3/30/23
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
10.82
|
70.6
|
438.8
|
627.5
|
758.4
|
EBITDA
1 |
-87.23
|
-123.4
|
-135.6
|
141.5
|
307.3
|
357.7
|
EBIT
1 |
-93.77
|
-135.5
|
-157.1
|
116.2
|
283.8
|
337.7
|
Operating Margin
|
-
|
-1,252.31%
|
-222.54%
|
26.48%
|
45.23%
|
44.53%
|
Earnings before Tax (EBT)
1 |
-87.02
|
-119.6
|
-137.4
|
396.8
|
264.1
|
623
|
Net income
1 |
-68.77
|
-94.22
|
-106.8
|
369.6
|
200.7
|
539.4
|
Net margin
|
-
|
-870.87%
|
-151.32%
|
84.22%
|
31.99%
|
71.12%
|
EPS
2 |
-1.083
|
-1.391
|
-1.579
|
4.911
|
2.664
|
7.220
|
Free Cash Flow
1 |
-68.69
|
-84.78
|
-148.1
|
100.3
|
219.6
|
304.5
|
FCF margin
|
-
|
-783.66%
|
-209.76%
|
22.86%
|
35%
|
40.15%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
70.91%
|
71.47%
|
85.12%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
27.14%
|
109.41%
|
56.45%
|
Dividend per Share
|
-
|
-
|
-
|
4.134
|
1.812
|
3.500
|
Announcement Date
|
4/30/19
|
4/27/20
|
3/26/21
|
3/28/22
|
3/30/23
|
3/29/24
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
143.7
|
155.1
|
123.5
|
152.6
|
-
|
179.7
|
116.9
|
159.7
|
226.8
|
112.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
49.9
|
60.36
|
49.34
|
61.49
|
-
|
98.09
|
23.99
|
62.14
|
117.7
|
63.59
|
Operating Margin
|
34.73%
|
38.92%
|
39.95%
|
40.29%
|
-
|
54.57%
|
20.53%
|
38.91%
|
51.89%
|
56.63%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
-
|
38.24
|
-
|
-
|
-
|
-
|
98.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
87.36%
|
EPS
2 |
-
|
-
|
-
|
-
|
0.5092
|
-
|
-
|
-
|
-
|
1.340
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/24/22
|
5/12/22
|
8/12/22
|
11/11/22
|
3/30/23
|
5/15/23
|
8/11/23
|
11/14/23
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
798
|
558
|
372
|
1,309
|
1,252
|
1,329
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-68.7
|
-84.8
|
-148
|
100
|
220
|
304
|
ROE (net income / shareholders' equity)
|
-10.7%
|
-10.6%
|
-13.1%
|
27.6%
|
10.9%
|
29.7%
|
ROA (Net income/ Total Assets)
|
-9%
|
-9.12%
|
-11.1%
|
5.04%
|
8.88%
|
10.4%
|
Assets
1 |
764
|
1,033
|
962.4
|
7,331
|
2,261
|
5,174
|
Book Value Per Share
2 |
13.70
|
12.50
|
11.50
|
25.40
|
23.90
|
25.10
|
Cash Flow per Share
2 |
0.2000
|
0.4700
|
1.010
|
8.570
|
4.720
|
4.590
|
Capex
1 |
20.6
|
5.36
|
58.8
|
1.98
|
3.19
|
5.82
|
Capex / Sales
|
-
|
49.58%
|
83.33%
|
0.45%
|
0.51%
|
0.77%
|
Announcement Date
|
4/30/19
|
4/27/20
|
3/26/21
|
3/28/22
|
3/30/23
|
3/29/24
|
|
1st Jan change
|
Capi.
|
---|
| +5.88% | 465M | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.35B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|